Pre-Open Stock Movers 8/17: (SKYS) (SCYX) (NVIV) Higher; (STEM) ((JASO) (CREE) Lower
- Wall St. rises amid robust GDP data, mixed earnings
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Sky Solar Holdings, Ltd. (Nasdaq: SKYS) 34.9% HIGHER; announced that the Company entered into a Letter of Intent with Solar Partnership Capital Ltd (“Solar Partnership” or “SPC”), a non-affiliate of the Company in certain Japanese projects, pursuant to which Solar Partnership confirmed its intention to acquire interests it currently does not own in 152 MW of solar projects from Sky Solar Japan K.K. (“SSJ”) and to take on certain specified liabilities associated with respect to those projects (the “Transaction Assets”) for a total purchase price of JPY17 billion (approximately $US165 million), subject to certain standard closing adjustments. All the other assets and liabilities of SSJ that do not constitute Transaction Assets will be transferred to a new entity.
StemCells (Nasdaq: STEM) 34.6% LOWER; STEM disclosed in an SEC filing on Tuesday night:
On August 16, 2016, StemCells, Inc., a Delaware corporation (the “Company”), announced that from the period beginning August 16, 2016 at 5:30 p.m. (Eastern Time) through Wednesday, August 17, 2016 at 4:01 p.m. (Eastern Time) (the “Exercise Period”) the Company will be accepting warrant exercises from the holders of its outstanding warrants to purchase common stock issued on April 29, 2015 (the “2015 Warrants”) at a reduced exercise price of $1.10 per share. Any exercises of the 2015 Warrants outside of the Exercise Period will continue to be honored at the $10.20 exercise price for the 2015 Warrants.
SCYNEXIS (Nasdaq: SCYX) 23.3% HIGHER; Guggenheim analyst, Louise Chen, initiated coverage on shares of SCYNEXIS with a Buy rating and a price target of $15.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) 17.2% HIGHER; announced that the ninth patient implanted with the Neuro-Spinal Scaffold™ in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between the two- and three-month evaluations. This is the fifth out of the eight patients (62.5% conversion rate) in follow-up to have had an AIS grade improvement to date.
Urban Outfitters (Nasdaq: URBN) 11.6% HIGHER; reported Q2 EPS of $0.66, $0.10 better than the analyst estimate of $0.56. Revenue for the quarter came in at $890.6 million versus the consensus estimate of $886.84 million.
Valeant Pharmaceuticals (NYSE: VRX) 10.4% HIGHER; Morgan Stanley upgraded Valeant Pharmaceuticals from Equalweight to Overweight with a price target of $42.
Cancer Genetics, Inc. (Nasdaq: CGIX) 9.7% HIGHER; announced that it received New York State approval for its Focus::Myeloid™ NGS-based panel for myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).
JA Solar Holdings (Nasdaq: JASO) 9.6% LOWER; reported Q2 EPS of $0.31, $0.38 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $619 million versus the consensus estimate of $698.12 million.
Cree (Nasdaq: CREE) 9.2% LOWER; reported Q4 EPS of $0.19, $0.01 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $388.4 million versus the consensus estimate of $385.83 million. For its first quarter of fiscal 2017 ending September 25, 2016, Cree targets consolidated revenue, which includes both continued and discontinued operations, in a range of $356 million to $378 million. Consolidated GAAP net income is targeted at $5 million to $6 million, or $0.05 to $0.06 per diluted share. Consolidated non-GAAP net income is targeted in a range of $10 million to $16 million, or $0.10 to $0.16 per diluted share. (The Street sees Q1 revenue of $397.6 million and EPS of $0.22.
21Vianet Group (Nasdaq: VNET) 7.7% LOWER; reported Q2 EPS of ($0.17), $0.08 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $137.1 million versus the consensus estimate of $128.17 million.
Lumber Liquidators (NYSE: LL) 7.4% HIGHER; announced the final resolution of the Proposition 65 lawsuit originally filed on July 23, 2014, in the Superior Court of the State of California.
MeetMe, Inc. (Nasdaq: MEET) 6.4% HIGHER; reiterated its financial guidance for the third quarter and full year of 2016 in response to recent volatility in the Company’s share price and in anticipation of upcoming investor meetings.
EnteroMedics Inc. (Nasdaq: ETRM) 6.2% HIGHER; announced the appointment of Gary Blackford to its Board of Directors, effective August 16, 2016. The Company also announced that Anthony Jansz will step down from the Board effective August 16, 2016.
Target (NYSE: TGT) 5.5% LOWER; reported Q2 EPS of $1.23, $0.11 better than the analyst estimate of $1.12. Revenue for the quarter came in at $16.2 billion versus the consensus estimate of $16.18 billion. Comps fell 1.1 percent, versus a drop of 1 percent expected. Target sees FY2016 EPS of $4.80 - $5.20, versus prior guidance of $5.20 - $5.40 and the consensus of $5.13.
American Eagle Outfitters (NYSE: AEO) 5.2% LOWER; reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $823 million versus the consensus estimate of $818.1 million. Comps rose 3 percent, versus an 11 percent increase for Q215. The company sees Q3 EPS of $0.40 - $0.41, versus $0.40. expected.
Lowe's Cos. (NYSE: LOW) 4.8% LOWER; reported Q2 EPS of $1.37, $0.04 worse than the analyst estimate of $1.41. Revenue for the quarter came in at $18.26 billion versus the consensus estimate of $18.3 billion. Comps rose 2 percent, versus growth of 4.1 percent expected. Lowe's Cos. sees FY2016 EPS of $4.06, versus the consensus of $4.06.
Popeyes Louisiana Kitchen (Nasdaq: PLKI) 4.2% LOWER; reported Q2 EPS of $0.47, in-line with the analyst estimate of $0.47. Revenue for the quarter came in at $61.7 million versus the consensus estimate of $63.39 million. Total domestic same-store sales were flat, compared to a 7.9% increase in the second quarter of 2015. System-wide same-store sales growth in the range of 1.0% to 2.0%, a decrease from previous guidance in the range of 2.0% to 3.0%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aytu BioScience (AYTU) Prices $8.6M Common Stock, Warrants Offering
- Quantenna Communications (QTNA) Prices 6.7M Common Stock IPO at $16/Share, at Upper-End of Expected Range
- Aeterna Zentaris (AEZS) Announces $7.56M Common Stock, Warrants Registered Direct Offering
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesMorgan Stanley, Definitive Agreement, Louise Chen, Pre Market Movers, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!